Ultragenyx Pharmaceutical (NASDAQ:RARE) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research note published on Wednesday morning,Benzinga reports. Cantor Fitzgerald currently has a $118.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical’s FY2025 earnings at ($4.44) EPS.

Several other research analysts also recently weighed in on the company. TD Cowen upped their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Royal Bank of Canada restated an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. JPMorgan Chase & Co. dropped their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. Wells Fargo & Company upped their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Finally, Piper Sandler lifted their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $92.43.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $42.94 on Wednesday. Ultragenyx Pharmaceutical has a one year low of $37.02 and a one year high of $60.37. The firm’s fifty day moving average is $44.63 and its 200 day moving average is $49.59. The firm has a market cap of $3.97 billion, a PE ratio of -6.64 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The firm had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company’s quarterly revenue was up 42.3% on a year-over-year basis. During the same period last year, the firm earned ($2.23) EPS. Research analysts predict that Ultragenyx Pharmaceutical will post -6.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Emil D. Kakkis sold 11,727 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the transaction, the chief executive officer now owns 2,183,985 shares in the company, valued at $92,229,686.55. The trade was a 0.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of RARE. Millennium Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 103.8% in the 2nd quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock valued at $76,065,000 after buying an additional 942,529 shares during the period. Alkeon Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 34.3% during the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock worth $167,301,000 after acquiring an additional 769,884 shares during the last quarter. Two Sigma Advisers LP raised its position in Ultragenyx Pharmaceutical by 123.4% in the third quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company’s stock valued at $54,872,000 after purchasing an additional 545,600 shares during the period. Frazier Life Sciences Management L.P. acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $17,468,000. Finally, Ikarian Capital LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $9,943,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.